Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $122

Canaccord Genuity maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $120 to $122.

Benzinga · 11/05/2019 16:31

Canaccord Genuity maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $120 to $122.